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1  Introduction 
1.  Since  the announcement  by the  UK  authorities  on  20 
March  1996  that the appearance  of 9 cases  of a  new 
variant  of CREUTZFELDT-JAKOB  disease  (nVCJD)  - a  rare 
human disease - could  be linked to exposure to bovine 
spongiform encephalopathy (BSE), European citizens have 
become  concerned  over  the  consequences  of  this 
likelihood for human health. 
Known cases of nvCJD currently stand at 15 (14 in the UK, 
1  in  France).  The  infectious  agent  and  transmission 
mechanisms for these diseases, which are always fatal, are e-
very  poorly  understood.  In  c:ddition,  there  is  no 
treatment at present. 
·  2.  In this context, a sizeable research initiative within the EU 
would appear to be essentie:JI.  Thts is why in April1996 the 
commission gave a group chaired by Prof. WEISSMANN the 
task  of  dra'.,ving  up  an  inventory  of  the  st3te  of 
knowledge and proposing research priorities on BSE. 
Since  20 June 1996,  the commission has  made public its 
intention of proposing an action plan for research ·on  BSE 
and CJD.  It set out this intention at the Research  council 
of 7 october 1996, indicating that supplementary funding 
would be needed. 
The research council of 7 october invited the commission 
to· reinforce  its  research  activities  on  BSE .. and  related 
diseases  and  to  present a communication  to the next 
Research council on 5 December.  This communication is 
in response to that invitation and includes an action plan 
in annex.· 
1 11  The  reauiremen~ 
1.  The report of the group chaired by Prof. WEISSMANN was 
made public on 16 october. It constitutes a full analysis of 
research  needs on  BSE  and  relateq  diseases.  There are 
numerous questions- 16 altogether- for which answers 
are required, both on practical aspects and basic research. 
Each question covers several research topics on average. 
2.  on the basis  of the WEISSMANN  report,  research  which 
needs to be carried out on  BSE  and related diseases can 
be divided into five areas (see table 1 of the action plan>: 
clinical  and  epidemiological  research  on  human 
spongiform encephalopathies (SE); 
the  infectious  agent  and  its  transmission 
mechanisms; 
diagnosis of SE; 
evaluation of the risk of SE; 
treatment and prevention of SE. 
Within  these  areas,  24  research  topics  have  been 
identified.  Given  the complexity of the subject, several 
research  projects per topic are often required. 
3.  From a careful analysis of the figures, the commission has 
evaluated funding requirements at 45.7  MECU  (table 1 of 
the action plan),  to which  5 MECU  should  be added for 
coordination (table 2 of the action plan),  i.e.  50.7  MECU 
overall. 
These  are  minimum  requirements  both  in  terms  of 
quantity of high priority research and overall cost. 
This analysis is  not surprising when one considers that a 
serious  research  project in  these  areas  costs  at least 1 
MECU  and  sometimes  more.  For  example,  the 
development and perfection of essential diagnostic tests 
and  the study of means  of transmission  are  extremely 
costly (7 .6 and 4.5  MECU  respectively). 
Reinforcement of coordination of research  activitie~ on 
TSE between Member states is also nee<;jed.  The cost of 5 
MECU for this may seem rela.ti_vely high compared with the 
2 lightweight coordination  which  is  usually  practised  in 
research  matters.  Here,  though, it is  a matter of very 
serious  coordination  with  a  view  to  harmonising  the 
collection of  data and diagnostic criteria for the detection 
and  identification of the disease(S)  concerned.  To  this 
end, the creation of databases and training programmes 
are both essential and, inevitably, costly. 
111  Funding 
1.  The  funding  of research  projects  on  TSE  can  only  be 
carried  out  through  the  3  "Life  Sciences" _  specific 
programmes,  BIOMED,  BIOTECH  and  FAIR.  The  Council 
decisions on these specific programmes set out indicative 
breakdowns between areas within the overall funding for 
each  of them  (the  Amount Deemed  Necessary).  only 
certain areas could incorporate research  projects on TSE 
in any significant way: 
BIOMED  2: 
BIOTECH  2: 
Area  3:  "Brain Research" 
Area  4.2:  "Research  on  Aids, 
Tuberculosis  and  other  infectious 
diseases" 
Area  Lt:  "Cell  communication  in 
Neurosciences" 
Sub-area  "Antmal Health", one of the 
22  sub-areas  of Area  4  "Agriculture, 
Forestry and Rural Development" 
At the Research council of 7 october, several delegations 
ruled out the possibility of BSE affecting the breakdown 
of  the  current  financial  envelope  of  the  Framework 
Programme between specific  programmes or even  the 
breakdown  between  areas  within  the  "Life  Sciences" 
specific programmes. 
This  is  why it is  not politically  possible  to carry  out a 
redeployment in favour of research on TSE: 
1  sub area 3.4 "Generic Science of Food" could be slightly concerned. 
sub area 4.2 "Quality Policy" could also be concerned. 
3 
1/L either between specific programmes, which would 
result  in  the  overall  funding  <Amount  Deemed 
Necessary) for the "Life Sciences" programmes being 
overshot by underusing other specific programmes; 
or between areas within the "Life Sciences" specific 
programmes. 
The only redeployment which is foreseeable is thus \Nithin 
the areas  of the "Life Sciences"  programmes which are 
relevant for research on TSE. 
2.  In order to finance the 50.7 MECU  requin~d for the action 
plan,  there are  three complementary  possibilities  <see 
table 1 of the action plan): 
2.1  Research projects on TSE currently being or about to 
be financed. 
These amount to 5.9  MECU,  of whicl1 1.5 MECU  have 
already been  allocated  in  the first BIOMED  call  for 
proposals, and 2.4 MECU and 2 MECU are about to be 
allocated ln the BIOMED and FAIR  calls for proposals 
which  closed  on  17  June and  20  september 1996, 
respectively. 
2.2  Redeployment  within  the  areas  of  the  BIOMED. 
BIOTECH and FAIR programmes relevant for TSE. 
The  total  sum  which  it  is  possible  to  redeploy 
amounts to 9.8  MECU  <8.8  MECU for FAIR,  1 MECU  for 
BIOTECH). 
The  situation within each  of the areas  relevant for 
TSE  is as follows: 
o_I310MED  2 
The  second  call  for proposals  which  closed  on  17 
June used up the last appropriations for areas 3 <18.5 
MECU)  and 4.2 <12.4  MECUL  several proposals on TSE 
were received under area 3.  some of them could be 
retained for a funding of around 2.4 MECU <see point 
2.1). 
The third ar.d last call for proposals was launched on 
4 15  september  and  does  not  cover  any  of  the 
relevant areas  as  all  the appropriations have  been 
used up <see above>. 
•BIOTECH  2 
The third call for proposals closed on 18 october and 
does not cover area 4. 
The fourttl and last call for proposals will be launched 
on 15 June 1997.  It will use up the appropriations for 
area 4 <4.9 MECUL  Of this sum, one could envisage 1 
MECU being used for  TSE, around 20% of the funding 
for this area. 
•FAIR 
Animal health, a relevant sub-area for  TSE is only one 
of 22  sub-areas of area  4.  This  means that there is 
only around  12  MECU  left for 1997  for all  animal 
health  areas,  to  be  shared  with  other important 
diseases  <salmonellosis,  rabies,  foot  and  mouth 
disease,  swine  fever>,  of  which  some  are 
transmissible to man.  In  this context, it would be 
difficult  to  provide  for  more  than  8.8  MECU  o~ 
redeployment in  favour of BSE,  i.e.  15%  of area  4 
and around 75% of research on animal health. 
A call for proposals for FAIR, as foreseen in the work 
programme, is planned for launch on 15 December. 
At the same time, the commission intends to launch 
a specific  FAIR  call  for proposals for BSE  using  8.8 
MECU.  However, it is clear from the outset that any 
possible redeployment within the FAIR  programme 
would  be. very  insufficient  Vlfith  respect  to  the 
financial needs and the subjects of projects limited 
to animal health which could be financed. 
2.3  supplementary funding 
35  MECU  of supplementary funding with respect to 
the  current  overall  funding  for  the  Framework 
Programn1e  are  thus  essential  for the  three  Life 
2  sub area 3.4 "Generic science on Food" could also be slightly concerned. 
5 Sciences specific programmes in order to respond to 
the minimum requirements of so MECU identified by 
the WEISSMANN  report. 
These 35 MECU would be attributed according to the 
subjects of the research themes (Cf table 1 of action 
plan> and will be divided up as follows: 
16 MECU for BIOMED 
7.5  MECU for BIOTECH 
11.5 MECU for FAIR 
IV  conclusion 
1.  In  parallel with this communication, the commission has 
adopted a communication on orientations with a view to 
a  revised  proposal  for a  financial  supplement  to  the 
fourth  Framework  Programme  for  research  and 
technological development.  These orientations propose 
setting aside 35  MECU for research on  BSE. 
The adoption in due course by the council and Parliament 
of  a  common  political  position  on  the  financial 
supplement containing  a substantial  extra  amount for 
research on TSE  is a condition for the commission being 
able to launch a specific joint call  for proposals for the 
three Life Sciences programmes, on the basis of its own 
powers. 
Thus, the EU would be in a position to respond rapidly to 
the expectations of European  citizens  by putting  into 
practice the recommendations of the WEISSMANN report 
with an  ambitious action plan. 
2.  In conc:usion, the commission hereby informs the council 
and the European  Parliament of its intention to launch' 
the  action  plan  on  TSE  research  annexed  to  thls 
communication, for a total sum of 50.7 MECU,  35 MECU of 
which is new funding. 
This  will  come  from  tt1e  financial  supplement to  the 
fourth  Frameworl<  Programme  for  research  and 
development, for which the commission  is  preparir.g a 
second revised proposal to be submitted to the council 
and European Parliament for opinion. 
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2 European Initiative on Research into Bovine Spongiform Encephalopathy 
and Subacute Spongiform Encephalopathies 
1.  Introduction 
Spongiform  encephalopathies  (SEs)  are  a group of fatal  transmissible neurodegenerative 
diseases  of humans (e.g.  kuru,  Creutzfeldt-Jakob  Disease  (CJD},  Gerstmann-Straussler-
Scheinker Disease (GSSD)) and animals (e.g.  scrapie,  bovine spongiform encephalopathy 
(SSE)). 
These diseases have become an increasingly important research area both because of their 
unique biology and also the recent situation concerning the epidemic animal prion disease, 
which led to legitimate  public  anxieties  over a  risk  to  human  health  from  eating  infected 
tissues. 
The  recent  identification  by  the  National  CJD  Surveillance  Unit  (Edinburgh,  UK),  the 
coordinator  of  the  European  network  on  epidemiological  surveillance  supported  by  the 
European  Community  Biomedical  and  Health  Research  Programme  (SIOMED),  of  an 
apparently new clinicopathological variant of CJD in fifteen teenagers and young adults has 
raised new concerns about the transmission of the SSE agent to man via the food chain. 
2.  The needs 
Despite existing basic and clinical research in  this field  it has not been possible to  identify 
the  nature  of the  agent,  and  many  factors  !n  the  epidemiology  of  SEs  are  yet  to  be 
explained. It is therefore essential to focus and stimulate research efforts at Community level 
and to mobilise new research teams in  order to attain a critical mass. 
The  need  to  intensify  research  activity  in  order  to  address  many  of the  questions  still 
outstanding in  relation to BSE was highlighted by the Agriculture Council of 1-3 April 1996. 
Similarly, at its meeting of May 1996,  the  Health Council concluded that the issue of SSE 
constitutes  a  problem in  the  field  of public health  and  therefore  all  appropriate  measures 
should  be  taken  to  eliminate the  risk  of possible transmission of the  disease.  Finally,  the 
Ministers of Research  at  the  Research  Council  of October 1996 emphasized the  need to 
improve cooperation and coordination  of research  efforts and  called upon the Commission 
to  reinforce  its  research  activities  on  topics  in  this  field  covering  both  basic and  applied 
biology and human and animal health aspects, as well as diagnostic aspects. 
These efforts, to be implemented by the Commission, and which may be  termed an  "action 
plan", will essentially be performed through the coordination of activities between all Member 
States  and a specific Call for Proposals. 
The action plan should identify the real needs in  terms of research priorities and budgetary 
position  based  on  the  most recent  experiences,  taking  into  account the  recommendations 
from the Weissmann Report and the Multidisciplinary Scientific Committee. It will also take 
into account ongoing Community research activities, including proposals received within the 
last  calls  of the  SIOMED  and  FAIR  programmes  and  work  under  way  and  planned  in 
Member States: 
3 3.  Current research activities in the field of  SEs at Community and national  level 
Research on  SEs has been  sponsored  at  EU  level  since  1990.  During that year,  and  in 
order to  give a  prompt response  to  the  needs  in  this field,  an  emergency procedure was 
launched and  1 MECU was allocated to  three  specific projects identified by the  Scientific 
Veterinary Committee as covering the most important areas for research investment in this 
field. 
The projects were implemented within the RTD programme in  the field of Competitiveness 
of Agriculture and Mana,gement of Agricultural  R~sources (1989·1993,  CAMAR, a specific 
programme of the 2nd Framework Programme), and were concerned with the isolation and 
identification  of the  infective  agent;  the  monitoring  of the  presence  of BSE  in  cattle  by 
examining  cattle  brains  after  a  negative  diagnosis  for  rabies;  and  the  assessment  of 
European rendering systems in order to determine their effectiveness against the scrapie and 
BSE agents. 
In  1991  an  additional project was sponsored, aimed at assessing modifications in  the prion 
protein as a pathogenetic mechanism for BSE and related disorders. 
The Commission has also been involved in the  organisation and financing  of the  following 




In  1990,  a  European  Community  seminar  on  "Subacute  spongiform 
encephalopathies" was organised.  The meeting was attended by scientists from 18 
countries,  representatives  of  the  World  Health  Organisation  (WHO)  and  the 
Organisation lnternationale des Epizooties (OlE).  The proceedings of this seminar, 
the  first authoritative book on  BSE, were  published for the Commission  by  Kluwer 
Academic Publishers. 
Similarly,  a  seminar on  the  issue of "Prion  diseases in  humans and  animals" was 
held  in  London  in  1991.  Over  100  participants  from  Member States  and  third 
countries attended. 
In  addition,  two  diagnostic  workshops  were  jointly  organised  by  the  European 
Commission  and the  Central  Veterinary  Laboratbry  of the  United Kingdom in  1990 
(16·20 July, "EEC workshop on  BSE diagnosis") and  1991  (8·11  April, "Spongiform 
encephalopathy diagnosis workshop"). 
This was further strengthened with the  adoption  of the  3rd  Framework Programme (1990· 
1994)  for research  and technological  development which  provided  the  basis  to  tackle  the 
issue of research on transmissible spongiform encephalopathies at European level.  Indeed, 
research  on  this  issue was  addressed  as  a  priority  within  several  European  Community 
research programmes, namely: 
* 
* 
The Agriculture and Agro-industry, including Fisheries, programme (1990-1994, AIR), 
which supported one project aimed at characterizing the nature of the BSE agent; 
The  Biomedicine and  Health Research programme (1990-1994,  BIOMED 1),  which 
supported  the  establishment  of  a  network  for  epidemiological  surveillance  of 
Creutzfeldt-Jakob  Disease  (originally  funded  by  Directorate  General  VI  in  1990, 
building  on  the  existing  EURODEM  project),  and  the  development of harmonized 
criteria  for the  neuropathological  diagnosis  of CJD  and  related  human  spongiform 
encephalopathies; 
4 *  The  Biotechnology  programme  (1990-1994,  BIOTECH  1),  which  supported  one 
project  on  the  molecular mechanisms  involved  in  the  pathogenesis  of SSE  and 
related  neurodegenerative  disorders,  and  also  aimed  at  developing  suitable 
experimental animal models. 
The network of epidemiological surveillance of CJD is, at present, the only existing structure 
able to  provide a systematic evaluation of the  incidence and the geographic distribution of 
this disease in the five countries involved.  Indeed, the Health Council at its last meeting (20 
May  1996)  proposed  that  this  structure  should  be  taken  as  a  model  to  implement  the 
surveillance of CJD in all Member States. 
In  September 1993, the Commission organised a consultation on  BSE with the European 
Community Scientific Veterinary Committee and the scientists engaged on research in this 
field  to  assess  the  scientific  information  available.  A  book  of  proceedings  entitled 
"Transmissible spongiform encephalopathies" was published by  the European ~ommission. 
In  1994,  a report depicting protocols for the  laboratory diagnosis and  confirmation of BSE 
and  scrapie was issued by  the Scientific Veterinary Committee. This report was produced 
in  consultation with all  Community research  laboratories  leaders in  the field  together with 
several laboratories from third countries. 
With the adoption of the 4th Framework Programme for RTD (1994-1998), reinforcement of 
prion  diseases  has  continued  within  the  European  Community  research  programmes 
(BIOMED, BIOTECH, FAIR), allowing this issue to be addressed with different methodologies 
and perspectives. This has resulted in the funding of three additional projects in the first call 
of the  BIOMED 2 programme. The most important one  is  using animal models to  address 
the  issue of interspecies transmission and  to  assess the  efficacy of the species barrier in 
limiting the transmission of BSE to humans. 
Although the  available resources are limited,  the second call for proposals of the BIOMED 
2 programme, which had a deadline of 17 June 1996, will  give the  possibility to  support a 
few proposals in  this field. 
Within  Member States  and  associated  countries,  research  in  the  field  of SEs has  been 
addressed at two levels: 
- Clinical research and surveillance of human SEs. 
- Basic biology of human and animal SEs. 
An overview of the activities undertaken at national level in  this field  is presented in  Annex 
1. This text, which is not exhaustive, has been compiled on the basis of information provided 
during the meeting of Directors-General for Research from Member States (held in Brussels, 
June 1996) aimed at exchanging information on activities undertaken ir, the field of SEs and 
establishing  mechanisms reinforcing  cooperation  and  coordination,  and  reports  presented 
Gt  the  last meeting  of the  Office  International  des Epizooties  (OlE),  held  in  Paris  on  8-10 
October 1996. 
Community activities have initiated .the  possibility of reinforcing the surveillance system for 
CJD and  related  diseases in  tho  countries involved and  have allowed the  establishment of 
inter-country  comparisons  and  the  development  of  harmonized  procedures  for  the 
identification and characterization of the disease(s). 
Such a  system  could  be  used  as  a base  for the  development of standard  procedures for 
disease identification .and surveillance in all  Member States. 
5 4.  Weissmann Group advice in the context of ongoing research activities 
The  Weissmann  Report  presents  a  thorough  analysis  of the  needs  in  the  field  of SSE 
research  and  addresses  two  types  of questions,  namely  questions  related  to  practical 
aspects of SSE and questions related to basic research on prion diseases. 
4.1.  Questions related to practical aspects. These include: 
4.1.1  Has SSE been transmitted to man perorally? 
The appearance since 1996 of an apparently new clinicopathological variant of Creutzfeldt-
Jakob  disease  in  fifteen  teenagers  and young  adults  (14  in  UK,  1  in  France)  has raised 
concerns about the possible transmission of the SSE agent to man via the food chain. 
Evidence in  favour of such  a possibility is  based  on  the  fact that the  SSE  agent can  be 
experimentally transmitted perorally to  mice,  mink,  cattle,  goats and  sheep,  and it could be 
that the strain-specific properties of the BSE agent are retained after passaging through a 
variety of animals such as sheep,  pigs, goats or mice and differ from those of the passaged 
scrapie agent. 
However, given the present state of the art, no definite conclusions on such a possibility can 
be reached. 
Several experimental approaches are proposed in order to throw more light on this question: 
0 
0 
"Comparison of agent strains  recovered  from  patients affected by  vCJD with  SSE 
and normal CJD, GSSS and FFI strains" (Table 1,  item 1.1 ). 
Such  experiments  are  partly  under  way  in  the  United  Kingdom  and  will  be 
underpinned by Community research activities but should be reinforced; 
"Extensiqn of a surveillance programme for CJD" (Table 1,  item 1.2). 
A  European  surveillance  programme  on  CJD  has  been  running  since  1990, 
contributing to the identification of the new variant of the disease.  Such an  initiative 
should  be  reinforced  in  order  to  include  all  Member  States  and  to  ensure 
identification at  European level of all  CJD cases which may correspond t? the new 
variant  of the  disease,  reinforcement  of epidemiological  analysis  of the  data  and 
identification of all epidemiological tools which may be necessary for broadening the 
assessment of risk transmission; 
"Experimental peroral transmission of BSE to primates".  Such an approach has not 
yet  been  pursued  but  it  is  considered  to  be  the  best way  to  answer the  above-
mentioned question" (Table 1,  item 4.1 ). 
4.1.2  Assessment of risk assoCiated with consumption of cattle-derived products 
"The assessment of risk for the transmission of SSE to  man as a function of BSE incidence 
in  the  cattle  population  and  of consumption  of cattle-derived  products is  one  of the  most 
important issues to be·solved.  In  order to  be able to perform a proper risk assessment, the 
following actions should be implemented": 
0 
0 
"Extension of the surveillance programme of BSE to all Member States, establishing 
wide and reliable standardized criteria for BSE detection and characterization". 
Such an  initiative will  allow to  obtain  exact figures on  the  incidence of the disease 
in the different Member States (Table  1,  item 4.2); 
"Determination of the incidence of covert disease in cattle", allowing to obtain  figures 
on the number of animals that, although symptomless at present, show the infectious 
agent in the nervous system (Table 1,  item 4.3); 
"Determination  of infectivity  titers  of brain,  spinal  cord  and  other tissues  of SSE-
infected cattle before and after outbreak of clinical disease" (T.c1ble  1,  ifern 4.4); 
6 0 
0 
"Determination  of  the  level  of  meat  contamination  with  brain/spinal  cord  after 
standard butchering procedures" (Table 1,  item 4.6); 
"Determination of oral  feeding  and  intracerebral dose responses to BSE  agent in 
primates and whether multiple dosing is cumulative" (Table 1, item 4. 7); 
"Determination of the utilization of offal in different human products prior to the ban 
and  the  consumption  of such  products  by  individual  age  groups  and  by  socio-
economic criteria" (Table 1,  item 4.5). 
Research  on  risk  assessment  ;n  relation  to  consumption  of cattle-derived  products  and 
transmission  modalities  has  so  far  not  been  supported  by  any  Community  research 
programme.  This  important  area  of research  could  be  addressed  mainly  in  the  FAIR 
programme, but also in the BIOMED programme. 
4.1.3  Determination  of possible infectivity in  BSE infected cattle-derived  products other 
than SBO (Table 1, item 4.4) 
At present, infectivity has been found in the brain, eye and spinal cord of diseased cattle and 
in the intestinal wall of calves experimentally infected with brain from SSE-infected cattle. 





"implement detection assays in  order to  examine all  products  entering  the human 
food  chain  (muscle,  milk,  cheese,  blood)  and  used  in  pharmaceutical  products 
(gelatin, collagen, etc.)" 
Evaluation of maternal risk factors for BSE in cattle (Table 1,  item 4.8). 
"Determine  infectivity in  placenta,  blood,  colostrum,  milk and  excrements of BSE 
cattle using sensitive assays" 
Transmission studies on a wide range of tissues from confirmed case~ of BSE have already 
been c::mied  out in the UK using mice as the model for bioassay.  These studies have had 
all  negative  results  to  date.  The objective  now is  to  repeat these  studies using  a  more 
sensitive bioassay. 
4.1.5  Did  BSE originate in  cattle and has it  been transmitted to  sheep in  recent years? 
(Table 1,  item 4.1) 




"To extend the surveillance of scrapie in UK sheep" 
"To  examine the  infectious  agent  derived  from  recent  cases  of sheep  scrapie  in 
regard to its strain properties" 
"To feed scrapie-infected brain from sheep to cattle and then monitor for appearance 
of BS  E-like disease" 
Can BSE be transmitted orally to pigs and chickens? (Table 1,  item 4.1) 
Intracerebral  inoculation  of  pigs  with  the  BSE  agent  leads  to  infection.  Peroral 
transmissibility  of BSE  from  BSE  cattle  brain  to  pigs  is  actually  being  tested  in  the  UK. 
Inoculation of chickens with BSE intracerebrally has not so far resulted in signs of disease. 
It  would  be  of interest  to  determine whether pig-to-pig  transmission  occurs,  in  particular 
orally. Therefore, it is proposed to: 
"feed and inject brain extract of experimentally BSE infected pigs to pigs" 
7 4.1.  7  Diagnostic research (Table 1,  item 3.2) 
"There is still no rapid, specific and sensitive method to detect human and animal SEs~  than 






"develop  a  sensitive  assay  in  transgenic  mice  carrying  cattle  transgenes  or 
cattle/mouse chimeric PrP genes" 
"explore surrogate markers" 
"explore the presence of PrPsc in tonsils and spleen of man" 
"sponsor a large-scale facility for assaying BSE infectivity in calves" 
On this issue, infectivity assays in  calves (currently the most sensitive assay for the BSE 
agent} are being performed on a large-scale basis by the Ministry of Agriculture, Fisheries 
and Food in the United Kingdom.  Also bioassays in mice are sensitive but may.not be able 
to detect low levels of the agent. 
Development of diagnostics mu.st be underpinned by basic research on the infectious agent. 
4.1.8 
0 
Inactivation of the BSE agent under different conditions  (Table 1, item 5.1 ). 
"Determine inactivation kinetics of BSE infectivity under conditions used currently in 
industry and explore additional procedures" 
This will allow· to determine the efficiency of BSE agent inactivation by procedures 
used in food and the pharmaceutical industry. 
Industry  studies  have  been  carried  uut on  inactivation  (i.e.  gelatin}  but these  should  be 
further  validated  under  the  FAIR  programme.  Provisional  results  of  a  study  on  the 
inactivation  of  SSE  and  scrapie  in  rendering  processes  (supported  by  the  CAMAR 
programme) have been received during 1996. 
4.1.9  Therapeutic research (Table 1,  item 5.2), 
No therapy is  at  present available.  Possible approaches for further research in  this field 
could jnclude: 
0  "specific inhibition of PrP synthesis" 
0  prevention of the conversion of PrPc into the pathological form PrPsc 
Not  addressed  so  far  by  any  Community  research  programme.  Should  be  based  on 
fundamental research which will establish and identify the nature of the agent. 
4.1.1 0  Can SSE-resistant cattle and  sheep be generated and would these be  of practical 
use? (Table 1,  item 5.3) 
It has been shown that inactivation of the prion protein (PrP) gene has no major detrimental 
effect on the mouse and it confers absolute protection against the disease.  Further research 
should be pursued on the means to: 
0 
"determine whether sheep  devoid of the  prion  protein  are  viable  and  resistant to 
scrapie", 
develop methods for generating cattle devoid of PrP. 
Transgenic cattle devoid of the prion protein may be of practical use in the pharmaceutical 
industry. 
8 4.2  Questions related to basic research on prion diseases 
The following issues deserving further investigation are as follows: 
4.2.1  The nature of the infectious agent 
The exact nature of the infectious agent is still not understood. Reinforcement of research 
in this area should be pursued with the aim of : 
* 
.. 
"Purification of the infected agent from SSE-infected cattle brain and analysis" (Table 
1,  item 2.1) 
"Identification of the  three-dimensional  structure of both  PrPc and  PrPsc  ..  (Table  1, 
item 2.4) 
Several Community research programmes are at present addressing this issue. 
4.2~  Multiplication of the agent 
In order to assess the issue of multiplication, the following approaches should be pursued: 
• 
* 
"Determine whether PrPc can be  converted into the infectious agent in vitro" (Table 
1,  item 2.4) 
"Determine which other components (receptors?,  etc)  are  required for propagation 
of the infectious agent" (Table 1,  item 2.2). 
4.2.3.  Pathogenesis (Table 1, item 2.2) 
The pathogenesis of the disease is  not yet understood. Further research should be pursued 
in  order to  acquire knowledge of the precise mechanism of pathogenesis, the cell types and 
tissues which can replicate the  infectious agent,  and the biochemical requirements for such 
a process. 
On the issue  of pathogenesis of SEs,  one  research  project is actually being supported at 
Community level. The project intends to assess the role of the prion protein in the activation 
of  glial  cells  as  the  first  mechanism  in  the  sequence  of  events  leading  to  final 
neurodegeneration, and is  being supported within the  BIOMED 2 programme. 
4.2.4.  Transport of the infectious agent (Table 1,  item 2.2) 
Further  research  should  be  pursued  on  the  issue  of  transport  of the  agent  within  the 
organism, in  order to: 
0 
0 
"determine where and how the agent enters the organism after ingestion" 
"determine how the agent passes from the periphery to the central nervous system 
and vice-versa". 
4.2.5.  Research on  different agent strains (Table 1,  item 2.3) 
Further research should be  pursued in order to: 
0  "explain what is the  molecular feature of the infectious agent that determines strain 
specificity" 
The mechanisms of prion propagation and the  characteristics of strain specificity are being 
partly assessed in an ongoing Community research project supported within the BIOMED 2 
programme. 
q 4.2.6.  Susceptibility of the host to the infectious agent (Table 1,  item 2.6) 
Research in this area should be pursued in  order to  : 
0  "identify  the  genetic  factors  which  contribute  to  susceptibility  and  determine 
incubation time" 
0  "determine which factors other than the  sequence of PrP  detennines the species 
barrier" 
The  identification  of genetic factors  which  could  contribute  to  confer susceptibility to the 
disease  are  currently  being  partly  assessed  in  an  ongoing  Community  research  project 
supported within the BIOMED 2 programme. 
4.2. 7.  Natural function of PrP (Table 1, item 2.4) 
. 
At present its function is unknown.  Research should be pursued in  order to obtain  further 
knowledge· of the  normal function  of this  protein  and  to  characterize what happens in  its 
absence. 
5.  Action plan for future activities 
The action plan has been established taking into account the recommendations put forward 
in the Weissmann Report and the Multidisciplinary Scientific Committee as well as analysis 
of ongoing Community and national research activities.  It will comprise two levels: 
- the coordination of activities between Member States; 
- a specific Call for Proposals, in order to create a critical mass by pooling the best research 
centres in Europe. 
5.1.  The coordination of activities between all Member States (see Table 2) 
Harmonisation of data collection and  diagnostic criteria for the  detection and identification 
of the disease(s) within Member States is essential for a proper comparatibility. 
~-oordi.nation of activities between Member States should therefore essentially ensure: 
a)  standardization  of  case  definitions  for. collection  of  data,  of  data  analysis  and  of 
dissemination of information in  order to  ensure a proper surveillance, 
b)  harmonised procedures for early detection and diagnosis of the disease(s}, 
c)  continuous updating and dissemination of scientific knowledge in this field, 
d)  fluent and rapid dissemination of these data, 
e)  activation of an early warning system in case of crucial developments, 
f)  exchange and mobility activities including training of research staff, 
g)  a continuous inventory of the progress of national research programmes, 
h)  the establishment of harmonized procedures and quality control of diagnostic methods for 
human and animal SEs. 
To this aim coordination of national specialized reference centres on SEs should be fostered, 
notably by the setting up of a research network of these centres aimed at: 
- the  establishment and  use of harmonized criteria  for collection  and  evaluation of data, 
case definition and classification of the disease(s) 
- the  development  of  an  efficient  and  on  line  communication  system  (through 
informatisation), 
- the exchange of staff. 
10 The participants should be able to harmonise and  share scientific and technical resources 
and  services provided by each agreed centre.  The network should have an  user-oriented 
approach providing European researchers with regular distribution of and access to relevant 
information and training activities  .. 
This coordination with Member States will need active input from the relevant Programme 
Committees. 
5.2.  Specific Call for Proposals 
The following areas of research have been identified (see Table 1,  point 7.1  of the Financial 
Statement): 
5.2.1.  Clinical, epidemiological and social research on  human SEs (see Table 1,  item 1) 
The continued analysis of incidence, clinical features and risk factors for diseases of the CJD 
type  in  European countries  is  likely  to  be  crucial in  an  assessment of any change  of the 
incidence of the disease(s). 
Reinforcement  and  further  development  of the  epidemiological  surveillance  of CJD  and 





a comparison of agent strains recovered from variant CJD patients with BSE and 
"normal" CJD, GSSS and FFI strains 
the  incidence  (including  reevaluation  of  previously  diagnosed  CJD  cases), 
geographical distribution and role of specific risk factors (genotype, diet, exposure, 
environment); 
the  process  of  identification  of  suspected  cases  and  the  sensitivity  of  the 
surveillance system; 
The infectious agent and its mechanisms of transmission (see Table 1,  item 2) 
The precise structure of the agent is  unknown, as are the mechanisms of transmission. 
Research reinforcing the characterization of the agent and the mechanisms involved in the 
pathological process should be pursued with the aim of assessing: 
2.1  the characterization of the agent; 
2.2  the mechanisms of propagation, transport and pathogenesis including elucidation of 
possible common links with other neurodegenerative diseases; 
2. 3  the  characterization of the  different strains,  including comparison of scrapie strains 
with BSE; 
2.4  the structure of both PrPc and PrPsc.  the normal function of PrP
0  and the mechanisms 
of conversion of PrPc into PrPsc; 
2.5  the basis of species barriers limiting inter- and intra-species transm:ssion; 
2.6  the susceptibility factors for the development of animal and human prion diseases. 
5.2.3.  Diagnosis of SEs (see Table 1,  item 3) 
Despite the urgent need,  no  early diagnostic tools are available at present.  Reinforcement 
of research allowing for the production of diagnostic tools should therefore be pursued with 
the aim of allowing: 
3.1  further development of cell cultures and banks for tissues and cells; 
3.2  development  of  rapid  and  sensitive  early  diagnostic  tests  including  surrogate 
markers, especially in  living animals and humans; 
11 3.3  development  of sensitive  assay  in  transgenic  mice  carrying  cattle  transgenes  or 
cattle/mouse chimeric PrP genes 
5.2.4.  Risk assessment of SEs (see Table 1,  item 4} 
Epidemiological evidence has raised concerns that the so called variant CJD is linked to the 
consumption of products derived from SSE-infected cattle. Moreover, the BSE agent is orally 
transmissible to a  number of species including:  mice,  mink,  cats,  cattle,  sheep,  goats and 
various other ruminants.  In order to perform an estimation of the risk of transmission of the 
disease, the following areas should therefore be pursued: 
4.1  an evaluation of SEs transmission modalities (including oral transmission} from cattle 
to man and other food animals, environmental vectors e.g.  mites. 
4.2  an extended surveillance programme of BSE and related diseases 
4.3  the identification of covert disease in  cattle 
4.4  the determination of the infectivity titers in cattle tissues and cattle derived products 
entering the human food chain or used in  pharmaceutical and cosmetic products 
4.5  the potential exposure of the human population 
4.6  determination of the level of meat contamination by brain/spinal cord after standard 
butchering procedures 
4.7  determination  of oral  feeding  and  intracerebral  dose  response  to  BSE agent and 
whether multiple dosing is cumulative 
4.8  investigation of possible biological mechanisms of maternal transmission of BSE 
5.2.5.  Treatment and prevention of SEs (see Table 1,  item 5} 
At present  no  therapies  are  available.  Reinforcement  of research  in  this  field  should  be 
pursued with the aim of allowing: 
5.1  Assessment and  development of inactivation procedures currently used in  industry 
(food, pharmaceutical, cosmetics) 
5.2  the development of therapeutic approaches; 
5.3  the  development of methods  for generating  cattle  and  sheep  devoid  of PrP  and 
practical use of these animals. 
6.  Priority setting and financial arrangements 
The European Union has been involved in  research on  SEs since 1990.  This initiative has 
resulted  in  the  support  of  11  research  projects  within  several  Community  research 
programmes  {CAMAR,  BIOMED  1  and  2,  BIOTECH  1  and  AIR)  with  an  overall  budget 
contribution of 3.545 MECU (2.120 MECU during the 2nd and 3rd Framework Programmes 
and 1.425 MECU for the 4th.Framework Programme). 
Table  1 depicts the  total  estimated  costs  and  additional resources  needed to  address the 
research  priorities  in  the  field  of BS E  and  prion-associated diseases  for the  period  1997-
1998. 
The specific Call for Proposals outlined in  item 5 identifies five  priority areas in  the field  of 
SEs deserving further investment. 
The  breakdown  provided  for  each  area  is  based  on  the  assumption  that  at  least  one 
research project and, in  several cases, more than one,  should be  supported in order to fully 
implement the research priorities outlined. 
12 The setting of a usual research Community project involves up to five research laboratories 
with an  average contribution per laboratory,  per year,  of 100,000 ECU.  This amount has 
demonstrated to  cover the  salary of one  scientist (66,000  ECU/year),  half the salary of a 
technician  (20,000  ECU/year)  and  the  necessary  consumable  and  equipment  material  to 
perform the research tasks to be carried out by the laboratory.  · 
For the implementation of a  concerted  action, where the  main  objective is the sharing of 
information  and  the  gathering  of  different  expertises  and  methodologies,  the  average 
contribution deemed necessary to implement the work is estimated to be  10,000 ECU per 
laboratory, per year.  This will cover the costs for travel meetings, short-term exchange of 
staff and exchange of material for each laboratory. 
For the implementation of a centralized facility,  defined as a unique general service tool for 
other projects supported by the  specific action plan in order to enable standardization, joint 
experiments,  data collection  and  analysis with access to  particular products,  experimental 
materials, specialised services (e.g primate research expertise), the Community funding may 
cover 100% of the costs of the costs of services rendered by the Centralized Facility to the 
research center, universities, undertakings and enterprises participating in shared cost and 
concerted actions. 
6.1  Total estimated costs and  additional resources needed to address the specific Call 
for Proposals 
Table  1  point  7.1  of the  Financial  Statement  provides  an  overview of the  total  financial 
resources needed to implement each of the areas depicted in the specific call for proposals. 
These include: 
6.1.1  Clinical and epidemiological research on human SEs 
The BIOMED 2 programme, key specific programme in  terms of research on  human SEs, 
will be in charge of the implementation of this area. 
At present the BIOMED 2  programme is  practically completed with all  Calls for Proposals 
having already been launched.  Strategies for the redeployment of financial resources could 
therefore  not  be  envisaged.  However,  it  is  expected that,  as  a  result  of the  last Call  for 
Proposals in  BIOMED 2,  one project could be supported. 
Therefore,  and  in  order  to  fully  implement  this  research  area,  additional  resources  are 
necessary. 
6.1.2  The infectious agent and its mechanisms of transmission 
The  implementation  of  this  research  area  could  be  done  within  the  three  specific 
programmes  (BIOMED 2,  BIOTECH 2 and  FAIR),  depending on  the  specific issues to  be 
tackled. 
At present, ongoing research activities in this area within the BIOMED 2 programme partially 
address issues such  as  the pathogenic mechanisms of prion diseases, the structure of the 
normal and abnormal prion protein, the basis of species barriers and the susceptibility factors 
for  the  development  of human  prion  diseases,  with  an  overall  Community contribution  of 
1.425 MECU.  In  addition,  and  as  a result  of the 2nd Call for Proposals of the BIOMED 2 
programme (deadline 17 June 1996), a further budgetary commitment is expected. 
Within the BIOTECH. 2 and FAIR programmes, a limited budget could be  rcshifted in  order 
to  address  specific  issues  such  as  the  mechanisms  of  propagation,  transport  and 
pathogenesis of the prion agent. 
13 Additional resources are therefore needed in  order to fully implement research in this field. 
6.1.3  Diagnosis of SEs 
This area of research will be implemented by the three programmes. At present, no ongoing 
Community research activities are implementing ·the outlined priorities. 
Ongoing  calls  in  the  BIOMED 2  and  FAIR  programmes  could  be  able  to  mobilise funds 
aiming  at  addre~  sing  the issue of the  development of rapid  and  sensitive  early diagnostic 
tests.  Similarly, an estimated budget could be reshifted towards this area of research from 
the BIOTECH 2 and the FAIR programmes. 
Therefore,  and  in  order  to  allow  a  proper  implementation,  supplementary  funds  are 
necessary. 
6.1.4  Risk  asses~ment of SEs 
The  research  areas  included  are  covered  by  the  BIOMEO  2,  BIOTECH  and  FAIR 
programmes. 
At  present,  no  ongoing  research  activity  within  the  Community  research  programmes  is 
addressing this i.ssue. 
The  possibility  of reshifting  financial  resources  within  the  FAIR  programme  towards  this 
domain could be E:nvisaged. This initiative will allow to initiate the financial support of projects 
addressing areas such as  the evaluation of BSE transmission modalities, the determination 
of the infectivity titers in  cattle tissues or the  evaluation of the risk of maternal transmission 
for BSE. 
Therefore, and in  order to fully implement the important aspect of the transmission modalities 
of BSE (including oral transmission) where studies on primates may be necessary (BIOMED 
2},  additional resources  are necessary. 
6.1.5  Treatment and  prevention of SEs 
The  area  cover;  research  approaches  aimed  at  developing  inactivation  procedures, 
therapeutic compounds and  prevention strategies and  could be  developed within the three 
specific programmes (BIOMED 2,  BIOTECH and  FAIR}, depending on  the  specific issue to 
be  tackled. 
At present, no ongoing Community research activities are dealing with these issues. 
The possibilities of reshifting resources towards the FAIR programme are envisaged and will 
allow to  initiate supporting research  i~ this area. 
Additional resources are tleeded to  allow a full implementation of the tasks. 
6.2  Total  estimated  costs  and  additional  resources  needed  for  the  coordination  of 
activities between Member States 
The total estimated costs necessary for the full implementation of this activity, based on  the 
assumption  of the participation of one laboratory per Member State,  are  depicted in  Table 
2,  point 7.1  of the rinancial Statement. 
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Clinicel,  epir!amio!ogice/ and social roseerch on hum  en SE's 
compare agent strains recovered from vCJD patients with BSE and "normal" 
CJD, GSSS and FFI strains; 0  • 
the incidence (including reevaluation of previously diagnosed CJD cases), 
geographical distribution and role of specific risk factors (genotype, diet 
exposure, environment);D • 
the process of identification of suspected cases and the sensitivity of the 
surve:tlar.ce system 
!he research on  risk perception of the population in  relation to pricn 
diseases;D 
The infectious agent and its mechanisms cf  transmission 
the characterization of the agent;D • 
the mechanisms of propagation, transport and pathogenesis (special 
attention will be given to the possibility of oral transmission) including 
elucidation of possible common Jinks with other neurodegenerative 
diseases;O • 
characterization of the different strains, compare scrapie strains with 
BSE;O* 
the structure of both PrP' and  PrP", the normal function of PrP' and the 
mechanisms of conversion of PrP' into PrP" in vitro;O • 
the basis of species barrier limiting inter- and  intra-species transmission;D • 
the susceptibiJ:ty factors for the development cf animal and human prion 
diseasesO • 
Diagr.r sis OF SE's 
further develo"ment of cell cultures, and banks for tissue!i and cel!s;O • 
development of rapid and sensitive early diagnostic tests including surrogate 
markers, specia!Jy in living animals and humans;O • 
development of sensitive assay In transgenic m!ce 0  • 
-
LW\w\u.X)St 
Priority  Tctal Estimated 
cost in  •• 
MECU's 
A  1.5 
A  2.0 
A  ·0.5 
A  0.5 
Total: 4.5 
A  2.5 
A  4.8 
A  0.8 
A  1.5 
A  1.4 
A  1.1 
Total: 12.1 
A  1.0 
A  7.6 
A  1.3 
Total: 9.9 
Existing EU  Prospects for EU  Possible EU  Additional resources  needed •• 
contribution •••  funding MECU's  funding with  MECU's 
MECU's  redeployment 
MECU's 
.-
1.5  Biomed 
0.5 Biomed  1.5 Biomed 
0.5 Bi::med 
0.5 Biomed 
Total: 0.5:  Total: 4.0 
2.5 Biotech/Fair 
0.4 Biomed  0.4 Biomed  0.5 Biotech  3.5 Biotech 
Biomed/Fair 
0.3 Fair  0.5 Bi::med/Biotech 
0.5 Biomed  0.5 Biomed  0.5 Bicmed I  Bio~ech 
0.5 Biomed  0.4 Bicmed  0.5 Bionned/Bio!ech 
0.1  Biorr.ed  0.5 Falr  0.5 Biomed 
Total: 1.5  Total: 1.3  Total: 1.3  Total: 8.0 
0.5 Biotech  0.5  Bio~ech 
2.0 Fair  1.5 Fair  3.5 Fair/Bicm/Bictech 
0.6 Blamed 
0.5 Fair  0.8 Biotech/Fair 















an evaluation of SE's transmission modalities (including oral transmission) 
from caltle to man and other food animals, environmental vectorsO • 
tended surveillance orooramme on BSE and  rei dlt:U  Ul~t'd~t!:::>W 
~s and cattle derived 
1 pharmaceutical and 
. 
'Y  brain/spinal cord after 
;e responses to BSE 
'maternel transmission of 
Treatment and prevention of  SE's 
Assessment and development of inactivation procedures currently used in 
lndustl'); • (food, pharmaceuticals, cosmetics) 
development of therapeutic approachesO • 
generation of cattle and sheep devoid of PrPD • 
A  '4.5  4.5 Biomed/Fair 
A  M 
I 
2.0  2.0 rair •••• 
A  2.0  2.0 Fair 
A  3.5  1.5 Fair  2.0 Fair/Biotech 
A  0.5  0.5 Biomed 
A  0.5  0.5 Fair  -----
A  1.0  0.5 Fair  0.5 Fair 
A  1.0  0.5 Fair  0.5 Fair  . 
Total: 15  Total: 5.0  Total: 10 
A  1.7  1.0 Fair  0.7 Fair/Biotech 
A  2.0  2.0 Biomed/Bictech 
c  0.5  0.5 Fair 
Total: 4.2  Total: 1.0  Total: 3.2 
~~-~---4~,;-_  ~---_- 1~5  . I  4-.~-l- -~~---I  30.0 
Priorities are: A>B>C 
*  Weissmann report 
0  Background for the proposal of an  European Initiative at the  Research Council of October 7,  1996 
**  The following  assumption is  made:  100.000 ECU's per laboratory per year (including  1 scientist for 12  months= 66.000  ECU,  1/2 technician  for 12 months= 20.000 ECU, 
consumables and equipment)  ·  ' 
**•  EU-contribution under IV FP 
••••  in collaboration with national authorities 
I 
~ 
L~nw\<>xos: TOTAL ESTIMATED COSTS AND ADDITIONAL RESOURCES NEEDED TO ADDRESS THE COORDINATION OF ACTIVITIES 
BETWEEN MEMBER STATES IN  . 
THE FIELD OF BSE AND SUBACUTE SPOt:JGIFORM  ENCEPHALOPATHIES (1997-1998) 
TABLE  2 
Research area  Priority  Total  Existing EU  Prospects  Possible EU  Additional resources 
Estimated  -contribution  for EU  ·  · funding with  needed** MECU's 
cost in ..  MECU's  funding  redeployment 
MECU's  MECU's  MECU's 
-~ 
A.  Standardization of case definitions for collection of data, of 
data analysis and  of dissemination of information in  order to  A  1.00  1.00 
ensure a proper surveillance 
B.  Harmonised procedures for early detection and diagnosis of  A  .0.50  0.50 
the disease(s)O 
c.  Continuous updating and  dissemination of scientific  A  0.35  '  0.35 
knowledge in  this field  0 
D.  Fluent and rapid dissemination of these data 0  A  0.35  0.~5 
E.  Activation of an  early warning system in  case of crucial  A  0.35  0.35 
I 
developments 0 
F  ..  Exchange and mobility activities including training  of  A  0.60 
~  0.60 
research staff 0 
G.  A continuous inventory of the progress of national_ research  A  0.35  0.35 
programmes 0 
H.  Harmonisation and control of diagnostic methods for human  A  1.50  1.50 
and animal SE's 0 
.  I  5.0  TOTAL  5.0 
o  Background for the  proposal of an European Initiative at the Research Council of October 7,  1996 
••  For  area  A  and  H  the  following  assuption  is  made:  +/- 75,000  ECU  per laboratory  in  each  Member State  and  as~odated c.ountries  for 2  years  (including  1/2  scientist, 
consumables, travel and  equipment) and additional 10,000 ECU to the laboratory responsible for the overall coordination. 
For areas  B,  C,  D,  F,  E the  following  assuption is made:  +/- 20,000 ECU  per laboratory in  each  Member State and associated countries for 2 years (including  1/4 scieniist, 
technician, equipment, consumables and travel costs) 
For area F,  the following  assumption is made:  +/- 35,000 ECU  per laboratory in each Member State and associated countries for 2 years. OVERVIEW ON NATIONAL RESEARCH ACTIVITIES 
IN THE FIELD OF BSE/CJD 
MEMBER STATES 
1.  Austria 
ANNEX 1 
Research  on  spongiform  encephalopathies (SEs)  in  Austria is  centred at the Department of 
Neuropathology and Neurochemistry, Institute of Neurology of the University of Vienna. 
The  main  areas  of research  in  this  centre  includes  the  epidemiology  (the  department  has 
performed an epidemiological study of the incidence of CJD in Austria) and neuropathology of 
human SEs (CJD and gerstmann-Straussler-Scheiker disease (GSS)). 
In  addition,  the above mentioned department coordinates a Community research programme 
gathering  100  European  neuropathological  and  basic  research  laboratories  dealing  with 
neuropathologic diagnosis  of,  and  tissue  based  research  in,  human  SEs.  The  network  has 
defined criteria for neuropathological diagnosis of,  and tissue handling in human SEs. 
2.  Belgium 
This country is involved in  research in the field of SEs in the following areas: 
*  Epidemiological surveillance of SSE/scrapie, funded by the Agricultural ministry. 
No specific programme on  SEs is set up at present. 
3.  Denmark 
No specific programme on SEs exists at present. A new national register for CJD has been set 
up and a programme on  mutation screening for PrP is  going to be  developed. 
4.  Finland 




Neuropathology of human SEs 
Surveillance of human SEs (familial form of CJD) 
Molecular pathology of SEs 
The work is  being carried out at the  University of Helsinki. At present, no  special programmes 
on  the subject have been set up. 
5.  France 
A  national reference  centre  for animal  SEs was  set up  in  1990 (CNEVA,  Lyon).  A  National 
Advisory Expert Committee for SEs has been established in  1996. 




Characterization of the french SSE strains (CNEVA, Lyon) 







Characterization of the number of infected cattle in a herd where a single case has been 
identified (CNEVA, Lyon) 
Research for new diagnostic tools 
Research  for criteria  of inactivation  of MBM  in  various  rendering  systems  (CNEVA, 
INRA, CEMAGREF, to be implemented) 
Transmission  studie~ (using  transgenic animals)  and  studies  on  the  structure of the 
agent and on the function of PrP. These include: 
Study of the role of the immune system in the development of the prion agent 
at early stages of infection 
Role of PrP in the development of the disease 
In vitro studies, using a cellular model, of normal and pathological  PrP 
Conformational studies on PrP structure 
Cellular  localisation  of normal  ar:d  pathologic  PrP  and. structure  of amyloid 
plaques 
Research on possibilities, using two experimental models, to block accumulation 
of PrP at different stages of the disease 
Analysis of transmission mechanisms of the disease 
Epidemiological research including research on risk factors for the development of SEs 
(genetic, diet, environmental): 
surveillance of CJD and related diseases 
research  on  genetic factors favouring the development of SEs and comparison 
with Alzheimer and related diseases 
Genetic and  clinic  follow-up  of a  cohort  of 1000  individuals  receiving  growth 
hormone apparently contaminated with the infectious agent  (1984-1985) among 
which 35 cases of CJD have been diagnosed. 
The above mentioned work is being carried out at the CNRS, Units 9026 (Bordeaux), 2420 and 
2431  (Gif sur Yvette) and  9045 (Vi!lejuif), INSERM, Units 415 (Lille),  153 and 360 (Paris), 180 
and  431  (Montpellier),  INRA  (Jouy-en-Josas,  Tours,  Toulouse),  CEA-DSV  (Fontenay-aux-
Roses). 
G.  Germany 
TSE research in  Germany is  supported by the  ministries of Research,  Health and Agriculture. 




Structure and function of PrP including the structure and structural transformation of the 
infectious prion protein and the structural mapping 
Pathogenesis, function and therapy including investigations on pathogenic mechanisms 
of SEs in cell cultures of PrP% mice, the use of PrP% mice as an experimental system 
for  the  investigation  of  infectivity  and  cell  biology  of  the  prion  proteins,  the 
characterization  of  the  prion  protein  domains  responsible  for  the  disease,  the 
chemoprophylaxis and chemotherapy of prion infections 
Diagnostics and transmission including the establishment of cell culture titration methods 
for the. dete~tioh of the  scrapie  agent,  the  oral  infection  of hamster with  the  scrapie 
agent and the production of antibodies against prion proteins of humans and animals 
This  work  is  being  carried  out  at  the  Oeutsches  Primatenzentrum  and  Institute  of 
Neuropathology  (Gottingen),  DKFZ  (Heidelberg),  Robert  Koch  lnstitut  (Berlin),  Institute  for 
19 Molecular  Biology  (Munchen),  Federal  Research  lnstitut  for  Viral  Diseases  of  Animals 
(Tubingen), lnstitut for Physiological Chemistry (Mainz), lnstitut for Physical Biology_(Dusseldorf) 
and GBF, Structural Research (Braunschweig). 
7.  Greece 




Comparative study of carbohydrates in BSE and normal cow brains 
Improvement of scrapie diagnosis and study of scrapie infectious agent 
Characterization  of  the  BSE  infectious  agent.  On  this  subject  the  University  of 
Thessaloniki (Department of Pharmacology) is coordinator of a Community research. In 
addition, this laboratory is participating to three other Community research projects. 
Sponsoring  bodies  are  the  Greek  National  Research  Foundation,  the  Greek  Ministry  of 
Development and the National Office of Programming in Cyprus. 
At present, no special programmes on SEs have been set up. 
8.  Ireland 
Research  in  this field  is  mainly developed at the Veterinary Research  Laboratory Abbottown 
(Dublin) and the Zoology Department University College of Dublin. 
The main area of research include the development of rabbit polyclonal antisera to a number 
of synthetic PrP peptides which have been assessed immunohistochemically for their ability to 
differentiate BSE and scrapie affected tissues from negative tissues. 
Recently, a Scientific Committee has been set up to establish priorities in this field. 
9.  Italy 




epidemiology of CJD and  other prion  related  encephalopathies in  humans and 
animals; 
identification of patients with mutations and/or polymorphisms in the PrPN gene 
collection  of CJD  patients  information  in  selected  institutions  and  studies  of 
familial clusters with identification of genotypes and possible point mutations. 
Neuropathology and basic research 
identification of new phenotypes for these diseases; 
study of synthetic PrP  peptides:  biological effects,  physico-chemical properties 
relevant to  biology, interaction with plasma membranes; 
study of cells with mutated PrPN fragments; 
interaction drug-amyloid in vitro and in vivo. 
The  National  Research  Council  (GNP)  has  recently  launched a strategic research  project on 
BSE covering the areas of: 
0  physiopathology of SEs 
0  research about transmission mechanisms between italian breeds. 
20 The  Ministry  of  Health,  through  the  Institute  of Zooprofilaxis  and  Veterinary  Diseases,  is 
sponsoring a programme on "Integrative measures for the permanent surveillance_ of BSE". 
The  lstituto Superiore  di  Sanita  is  supporting  the  National  Registry  for Surveillance of CJD 
(coordinator: Prof. M.  Pocchiari}. 
The two main institutions in  Italy developing research in this field are the  lstituto Superiore di 
Sanita (Rome) and the lstituto Neurologico Carlo Besta (Milan). 
10.  Netherlands 






Development of tools for diagnostic methods on scrapie and BSE 
Antigenic studies of bovine prion protein  · 
Immunohistochemical detection of PrP in brain for scrapie diagnosis 
Immunohistochemical detection  of prion protein on  lymphoid tissues of diseased  and 
infected sheeps 
Genetic resistance to  scrapie 
The above mentioned work is being carried out at the Institute for Animal Science and Health 
(ID-DLO} Lelystad.  In addtion, this Institute is coordinator of a Community research programme 
aimed at assessing the role of PrPsc in glial activation. 
This country has also been deeply involved, through the work carried out at the Department of 
Epidemiology  and  Biostatistics  (6rasmus  University  Medical  School),  in  the  epidemiological 
surveillance of CJD, as part of the Community research project on surveillance for this disease. 
The Dutch Health Council is  at present preparing a strategy for research on  SEs which will be 
available soon. 
11.  Portugal 
A national programme on surveillance of scrapie has been recently set up. They are also setting 
up the basis to  develop a  n~tional registry for CJO. 
12.  Spain 
No specific programme on  SEs research exists at present. This country has been taking part, 
as  an  observer,  to  the  European  surveillance  network on  CJO  and  is  setting  up  a  national 
register for the disease. 
13.  Sweden 
No specific programme set up for SEs.  No  BSE, few cases of scrapie 
14.  United Kingdom 
Priorities for government research on animal SEs are currently based on specific needs as they 
are identified and advice from the Spongiform Encephalopathy Advisory Committee (SEAC). 
21 The Ministry for Agriculture,  Fisheries and Food (MAFF) programme is complemented by the 
research  programmes  of  the  Biotechnological  and  Biological  Science  Research  Council 
{BBSRC);  the  Medical  Research  Council  (MRC);  the  Department  of Health  (DH)  and  the 
Wellcome Trust. 
Coordination between these group is achieved by liaison at several levels most recently through 
the  Transmissible  Spol"!gifonn  Encephalopathy  Research  and  Development  Funders 
Coordination Group, chaired by the Department of Health. 
Five main areas are addressed (as defined in the SEAC report, 1995) covering both human and 
animal prion diseases: 
a)  Nature of the agent 
Research  on  this  issue  is  being  sponsored  by  the  MAFF,  !he  BSEP,  the 
Biotechnological and  Biological Science Research Council (BBSRC), the MRC, 
the BBSRC/MRC Core and the Wetlcome Trust.  Institutions involved include the 
Universities of Edinburgh, Reading, the Imperial College of Science, Technology 
and Medicine  of London,  the Animal  Health Trust and  thr::  Institute for Animal 
Health. 
b)  Pathological changes 
Research  in  this  field  is .. being. carried  out· by  the  Universities  of Edinburgh, 
Birmingham, Nottingham, the Imperial College of London, the Institute of  Zoology 
and  the  Central  Veterinary  Laboratory (CVL).  Sponsoring  bodies  include  the 
MAFF, BBSRC/MRC,  the MRC, the BSEP and the Wellcome Trust. 
c)  Transmission studies including transgenic animals 
Substantial research  in  this field  is  being performed at the  Neuropathogenesis 
Unit of the Institute for Animal Health (NPU, Edinburgh), University of Cambridge 
and Imperial College of London, the CVL, the Scottish Agricultural College and 
the  Agricultural  Development Advisory Board.  Sponsoring  bodies  include  the 
MAFF, BSEP, the BBSRC/MRC Core and Wellcome Trust. 
d)  Control of SSE epidemic 
Research on this issue is being sponsored mainly by the MAFF, at the NPU, the 
CVL,  the  Agricultural  Develcpment  Advisory  Board  and  the  University  of 
Edinburgh. 
e)  Applied questions including CJD surveillance 
CJD has been monitored nationally since 1990.  This issue is being carried out 
at the  National CJD Surveillance Unit (Edinburgh},  the  NPU, the CVL and the 
Imperial Coilege of London, St. Mary's Hospital, and is mainly supported. by the 
MAFF, DH,  Scottish Home and Health Department (SHHD), EC and MRC. 
A  specific  Coordination  Programme  on  Health  Aspects  of  Transmissible  Spongiform 
Encephalopathies (S.Es) has been recently set up in this country, with major fundings  from the 
Agricultural Ministry, the Medical Research Council and the Welcome Trust. 
22 The  MRC,  jointly  with  the  Department  of Health,  has  proposed  a  10 year initiative  to  be 
developed in two 5-year phases.  This initiative intends to strength~n research capacity (skills 
and infrastructure), increase collaburation between existing centres of expertise and to improve 
understanding by public and health professionals of prion diseases and associated risks. 
A  call  for proposals  has  recently  been  launched  in  identified  areas.  The programme  has  a 
strong human health orien!atlon with broad biological approach. 









Molr'cular,  celllllar,  genetic and  functional  approaches  to  elucidating  mechanisms of 
TSEs transmission, PrP replication, pathogenesis and clinical progression 
Integrated  molecular,  epidemiological  and  clinical  approaches  to  understanding  the 
cause{s) of sporadic CJD 
Biological  and  epidemiological  relationship  between  BSE  and  CJD  and  atypical 
dementias 
Early disease progression and diagnosis in life 
Analysis, perception and communication of risk in relation to CJD 
The biological function of normal PrP 
The molecular structure of prion proteins 
Rational approaches to developing therapy 
ASSOCIATED COUNTRIES AND THIRD COUNTRIES 
1.  Norway 





Norwegian College of Veterinary Medicine 
Prevalence studies of scrapie changes in  scrapie affected herds 
Genetic disposition of scrapie in Norwegian herds 
Comparative studies of absorption and persistence of scrapie-agent in intestine 
and lymphatic tissues in sheep and CDJ in humans 
Comparative studies .of post mortem changes in scrapie affected sheep and CJD 
in humans 
Survey on genetic disposition in  sheep herds for factors involved in  the normal 
function of prion proteins and the development of disease. 
Central Veterinary Laboratories 
Development of sensitive methods for detection of prion proteins in vivo 
Epidemiological studies of risk factors in  outbreaks of scrapie in  sheep herds 
National Institute of Public Health 
Epidemiological studies of risk factors involved in development of CJD in humans 
Improved surveillance of CJD and  other human spongiform encephalopathies in 
Norway by establishing criteria for diagnosis 
Development of models of cooperation between human and veterinary medicine 
in the field of prion diseases 
The three above mentioned institutions will be  in  charge of implementing the proposed plan. 
23 2.  Iceland 
In  Iceland  there  is a  specific knowledge  on  the  pathology  and  epidemiology of  scrapie,  as 
scrapie has been endemic in some parts of this country. The work carried out at the Institute 
of Experimental  Pathology  at Keldur has been  the  basis  for  the  eradication  programme of 
scrapie in Iceland. 







Research  on  the effect of prion gene  genotypes on  scrapie susceptibility in Icelandic 
sheep 
Study of mutations and DNA polymorphism in three CJD patients in Iceland. 
Switzerland 
Two reference centres for human and animal SEs 
In  situ  hybridization  and  immunochemistry  for  PrP  in  BSE  (Institute  of  Animal 
neuropathology, Bern) 
Case  control  study  I  BSE  risk  assessment  in  Switzerland  (lnstitut  for  virology  and 
immunoprophylaxis, MittelhaGsem). 
24 FINANCIAL STATEMENT 
1  TITLE OF OPERATION 
Communication  from  the  Commission  to  the  Council  relating  to  research  on 
bovine  spongiform  encephalopathy  (BSE)  and  subacute  spongiform 
encephalopathies. 
2  BUDGET HEADING  INVOLVED 
Fourth FP: 
3  LEGAL BASIS 
Biotechnology- B6 7141 
Biomedicine- B6 7142 
Agriculture and fisheries- B6 7143 
Council  Decision  No  94/912/EC  of 15  December  1994  adopting  a  specific 
programme in  the  field  of biotechnology.  Council  Decision No 94/913/EC of 
I 5 December I 994 adopting a specific programme in the field of  biomedicine and 
health.  Council Decision No 94/805/EC of23 November 1994 adopting a specific 
programme in the field of agriculture and fisheries. 
Decision  No  616/96/EC  of  the  Council  and  the  European  Parliament  of 
25  March  I 996. 
4  DESCRIPTION OF OPERATION 
Despite current efforts in fundamental and clinical research on bovine spongiform 
encephalopathy (BSE) and subacute spongiform encephalopathies, it has to  date 
not been possible to  identify the nature of the infective agents of these diseases 
and numerous epidemiological factors of human spongiform encephalopathies. 
However, these factors  must be  identified for the fight against these diseases to 
be effective.  Consequently, it  is  essential to  mobilize the  scientific community 
and stimulate research efforts at Community level.  These efforts will require the 
mobilization of new research teams so  as  to  attain a critical mass. 
In  view of the  above,  the  fundamental  objective  of this  communication  is  to 
strengthen the activities of research on bovine spongiform encephalopathy (BSE) 
and subacute spongiform encephalopathies. 
This objective involves a two-pronged approach: 
coordination of national activities; the work to be undertaken on the basis of a call  for additional proposals 
specifically in the fields of  clinical and epidemiological research, infective 
agents  and  their  modes  of  transmission,  diagnosis,  risk  assessment. 
treatment and prevention. 
5  CLASSIFICATION OF EXPENiliTlJHE 
Non-compulsory expenditure/Differentiated appropriations 
6  TYPE OF EXPENDITURE 
Shared-cost actions consisting ofRTD projects and demonstration projects 
benefit from a contribution not exceeding 50%. 
Universities and other research centres taking parting in RTD projects and 
demonstration projects  that  cannot,  in  the  Commission's opinion,  show 
sufficiently accurate proof of their total costs, determined on the basis of 
an analytical  accounts .system,  will  be  financed  at the rate of 100% of 
additional costs. 
For concerted action, the contribution may go up to  100% of additional 
costs. 
7  FINANCIAL IMPACT 
7.1  Appropriations required (in MECU) 
The appropriations  necessary  to  attain  the  objectives set out at point 4 
above form part of  the increase provided for in the Proposal for a decision 
of the European Parliament and the Council on the second adaptation of 
Decision Ill  0/94/EC, as adapted by Decision 616/96/EC, relating to the 
fourth framework programme for research, technological development and 
demonstration projects (1994-98), which is subject to the approval, in the 
co-decision procedure, of  Parliament and the Council and to the prior grant 
of funds by the budget authority. 
From a financial point of view, this financial statement concerns only the 
breakdown  of  the  following  sums  into  commitment  and  payment 
appropriations between 1997 and 1999+: 
Coordination of  Priority research  Total 
activities 
Biotechnology  7.5  7.5 
Oiomedicine and  3.5  12.5  16 
health 
Agriculture and  1.5  10  11.5 
fisheries 
This overall estimate rna  be detailed  urcl  y  'p  y indicative!  y,  m  accordance 
with the data shown in Tables 1 and 2 below. 
2 TOTAL ESTIMATED COSTS AND ADDITIONAL RESOURCES NEEDED TO ADDRESS THE RESEA.RCH 
PRIORITIES IN THE  FIELD OF SSE AND SUBACUTE SPONGIFORM ENCEPHALOPATHIES (1997·1998) 
( 
TABLE 1 
Research area  Priority  Total Estimated  Existing EU  Prospects for EU  Possible EU  Additional resources  ne~C'ed " 
cost In ••  contribution •••  funding MEClfs  funding with  MECU's 
' 
MECU's  MECU's  redeployment  .  MEClfs 
. 
1.  ClinicRI,  epidemiological and social research on human SE's 
1.1  co~pare agent strains recovered from vCJD patients with BSE  and "normal"  A  1.5  1.5  8icme.:1 
CJD, GSSS and  FFI  str2ir-~s: 0  • 
1.2  the  incidence (including reevaluation of previously diagnosed CJD cases),  A  2.0  0.5 Biomed  1.5 Bi:med 
c;<?ograp11ical dislribu!ion and role of specific risk factors (genotype, diet 
er.posure, environment);O • 
1.3  the process of ider1ti~cation of suspected cases and the sensitivity of the  A  ·0.5  0.5 Biome:l 
surveillance system 
1.4  ttH!  research on  risk perception of the  population In  relation to prion  A  0.5  0.5 Biomed 
diseases;D  Total: 4.5  Total: 0.5:  Total: 4.0 
2.  Th9  i.'1fectious egent end its mechanisms of transmission 
2.1  the  chuacterization of the agent;D •  A  2.5  2.5 Bio:echiFair 
22  the  mechanisms of propagation. transport and  pathogenesis (special 
attentiorl wi!l be  given to  the  possibility of oral transmission) including 
elucidation of possible common links with other neurodegenerative 
diseases~D •  A  4.8  0.4 Biomed  0.4  Bi:=~med  0.5 Biotech  3.5 Bio:ech 
2.3  characterization of the  different strains, compare scrapie strains with  Biomed/Fair 
BSE:o·  A  0.8  0.3 Fair  0.5 Bicmed/Biotec!\ 
2.4  the  structure of bo:h PrP' and PrP", the normal function of PrP' and  the 
mechanisms of conversion of PrP' into PrP" in vitro;O •  A  1.5  0.5 Biomed  0.5 Biomed  0.5 Biomed I Bio:e:h 
2.5  the  basis of species barrier limiting inter- and intra-species !ransmission;D •  A  1.4  0.5 Biomed  0.4 Biomed  0.5 Biomed!Bio!ech 
2.6  the  susceptibility factors for the development cf animal and human prion 
diseasesO •  A  1.1  0.1  Biomed  0.5 Fair  0.5 Bio:r.ed 
Total: 12.1  Total: 1.5  Total: 1.3  Total: 1.3  Total: 8.0 
3.  Oiagr,r sis OF  SE's 
3.1  further devetonment of cell cultures, and banks for tissue$ and cetls;O •  A  1.0  0.5 Biotech  0.5 Bio:ech 
3.2  development of ra;:~id and sensitive early diagnostic !es!s including surrogate 
m:uters, special:y In  living animals and humans;O •  A  7.6  2.0 Fafr  1.5 Fair  3.5 Fair/Bi~m/Siolecl'l 
3.3  devolopm~nt of sensitive essay In  transgenic mice 0  •  0.6 Blamed 
A  1.3  0.5 Fair  0.8  Bic!ech/F~:r 





I 4.  Risk assessment of SE's 
4.1  an  evaluation or SE's transmission mbdalities (including oral transfT'ission)  A  4.5  - 4.5 Bio .  ..,-,e::YFair 
from cat!le to  man and  o:her food animals, environmental vectorsO •  ..  -- ....  ~. 
42  extended survei!lance programme on SSE  and  rP.Iated  diseasesO •  A  2.0  I  2 :J  Fa'r •••• 
4.3  Identification of covert disease In  cattle •  A  2.0  2.0 Fair 
4.4  determination cf the  Infectivity titres in  cattle t1ssues  and cattle derived  ' 
.. 
products entering the human food chain or used in  pharmaceutical and  A  3.5  1.5  ~"ai•  2 0 Fai• 5 c:ech  i 
cosmetics poductsO •  , 
4.5  !he potential  exposur~ of the human population 0.  A  0.5  J 5 s,.:,...ed 
4.6  determination of the level or meat contamination by brain/spinal cord after  A  0.5  0.5 Fair 
stand2rd bu!chering procedures • 
'  ... ·--
! 
4.7  determ'na\ion o! oral feeding and intracerebral dose  respor~ses to BSE  A  1.0  0.5 Fair  0.5  Fair  i 
agent and whether mu:liple doses is cumulative •  ' 
4.8  investigation of possible biological mechanisms or maternel transmission or  A  1.0  0.5 Fair  ..  0.5 Fair  .  --·' 
SSE •  '  . 
Total: 15  Total: 5.0  Total: 10  I 
5. 
Treatm~nt and prevention of SE's  ... 
I''  I 
5.1  Assessment and development of inactintion procedures currently used in  A  1.7  1.0 Fair  G.7  Fa'r.'3iotech  i 
Industry; • (!cod, pharmaceuticals, cosmetics)  ' 
5.2  develc~rnent cf therapeutic approachesO •  A  2.0  2.0 Si:r.:ediBictech  . 
5.3  ge~erati:on of catt!e and sheep devoid cr PrPO •  c  0.5  · 0.5 Fair 
! 
Total: 4.2  Total: 1.0  ictal: :!.2 
TOTAL  45.7  1.5  4.4  u  . 30.0 
i 
' 
Priorities are:  A>B>C 
Weissmann report 
o  Background for the  proposal of an  European Initiative at the  Research Council of October 7,  1996 
••  The  following  assumption is  made:  100.000 ECU's per laboratory per year (inclu.ding  1 scientist for 12  mo.nths = 66.000  ECU,  1/2  technician  for 12.r;.c:;:;,s = 20.000 ECU, 
consumables and equipment)  ·  ·  '  • 
•••  EU-contribution under IV FP 
••••  in  collaboration with national authorities 
.....  ..  ~ " 
.t .. 
~ l,:  ..... '·~·..-c-·• TOTAL ESTIMATED COSTS AND ADDITIONAL RESOURCES NEEDED TO ADDRESS THE COORDINATION OF ACTIVITIES 
BETWEEN MEMBER STATES IN  . 
THE FIELD OF SSE AND SUBACUTE SPON~IFORM  ENCEPHALOPATHIES (1997-1998)  .  . 
TABLE 2 
Research area  Priority  Total  Existing  EU  Prospects  Possible EU  Additional resources  I 
'  .  Estimated  . contribution  for EU  ·  ·  funding with  needed•* MECU's 
cost in  ••  MECU's  funding  redeployment 
MECU's  MECU's  MECU's  ·--
A.  Standardization of case definitions for collection of data, of 
data analysis and  of dissemination of information in  order to  A  1.00  1.00 
ensure a proper surveillance 
B.  Harmonised procedures for early detection and diagnosis of  A  .0.50  0.50 
the disease(s)O 
c.  Continuous updating and dissemination of scientific  A  0.35  '  0.35 
knowledge in  this field  D 
D.  Fluent and rapid dissemination of these data 0  A  0.35  0.~5  I 
I 
£.  Activation of an  early warning system in  case of crucial  A  0.35  0.25 
developments 0  I 
F.  Exchange and mobility activities including training of  A  0.60  ~  0.60  l 
research staff 0 
G.  A continuous inventory of the progress of national_ research  A  0.35  0.35 
programmes 0  ! 
H.  Harmonisation and control of diagnostic methods for human  A  1.50  1.50 
and animal SE's 0 
TOTAL  5.0  5.0 
·-
o  Background for the  proposal of an European Initiative at the Research Council of October 7,  1996 
••  For  area  A  and  H  the  following  assuption  is  made:  +/- 75,000  ECU  per laboratory  in  each  Member State  and  associated  c.ountries  for  2  years  (including  1/2  scier.~is 
consumables,  travel  and  equipment) and additional 10,000 ECU  to  the  laboratory responsible for the overall coordination. 
For areas  8,  C,  D.  F,  E the  following  assuption is  made:  +/- 20,000 ECU  per laboratory in  each Member State and  associated countries for 2 years (including  1/4  sc:entis 
technician,  equipment. consumables and travel costs) 
For area  F,  the  following  assumption is made: +/- 35,000 ECU per laboratory in  each Member State and associated countries for 2 years. 7.2  Indicative schedule of appropriations' 
For the specific "Biotechnology" programme- Budget heading: B6- 7141 
(In  MECU)  1995  1996  1997  1998  19991  TOTAL 
Commitment  70.037  230.000  132.000  155.963  PM  588.000 
appropriations
1 
Additional  2.250  5.250  7.500 
commitment 
appropriations 
Payment  19.789  115.666  124.200  163.000  165.345  588.000 
appropriations
1 




For the specific "Biomedicine" programme - Iludgct heading:  B6 - 7142 
(In  MECU)  1995  1996  1997  1998  1999t  TOTAL 
Commitment  37.833  126.000  90.000  104.167  PM  358.000 
appropriations 
1 
Additional  4.800  11.200  16.000 
commitment 
appropriations 
Payment  10.831  49.000  85.800  95.000  117.369  358.000 
appropriations 
1 
Additional  9.600  6.400  16.000 
payment 
appropriations 
For  the  specific  "Agriculture  and  fishcrics"programmc  - Iludgct  heading:  Il6  -
7143 
(In  MECU)  1995  1996  1997  1998  1999+  TOTAL 
Commitment  120.737  181.000  162.000  182.763  PM  646.500 
appropriations 
1 
Additional  3.450  8.050  11.500 
commitment 
appropriations 
Payment  I  9.768  70.000  114.700  230.000  212.032  646.500 
appropriations 
1 
Appropriations of  the -lth  FE',  as included in  PDB  !997. 
3 I 
Additional  6.900  4.600  11.500 
payment 
appropriations 
The final  annual sums will  be determined by the Budget Authority. 
7.3  Administrative and  personnel expenditure 
With regard  to  administrative expenditure, the programmes must ensure 
that the total sum of the financial supplement allocated is by priority used 
to  finance research projects (as provided for in the proposal referred to in 
point 4 above). 
8  ANTI-FRAUD I\IEASlJRES 
There is a whole range of administrative and financial checks at all stages of the 
procedure for awarding and executing research contracts, including the following: 
Prior to conclusion of the contrnct 
Initial  selection of proposals on the  basis of the  scientific  value of the 
project and of an assessment as to  whether the research costs quoted arc 
realistic  in  relation  to  the  nature  of the  research,  its  duration  and  its 
potential impact. 
Analysis  of the  financial  data  transmitted  by  the  proposers  on  their 
application form. 
After the contract has heen signcl 
Scrutiny  of statements  of expenditure  prior  to  payment,  carried  out  at 
several  levels (financial  manager, scientific officer). 
Internal audit by the financial controller. 
On-the-spot checks enabling the detection of errors or other irregularities 
through an examination of the supporting documents.  In order to  make 
these checks more effective, the Commission's departments have set up an 
audit unit which brings together the results of all  the checks performed. 
These  checks  arc  either  carried  out  by  members  of the  audit  unit  or 
entrusted to auditing companies with which the Commission has concluded 
framework contracts, under the supervision of  officials from the audit unit. 
On-the-spot  inspection  by  the  financial  controller  and  by  the  Court of 
Auditors of the European Union. 
4 9  ELEMENTS OF COST-EFFECTIVENESS ANALYSIS 
9.1  Specific and quantifiable objectives 
The  general  objective  as  set  out  in  point 4  encompasses  six  specilic 
objectives, which may be classified as follows: 
(a)·  Priorities ofreseareh into bovine spongiform encephalopathy (BSE) 
and subacute spongiform encephalopathies; 
clinical and epidemiological research on human spongiform 
encephalopathies; 
infective agents and their modes of transmission; 
diagnosis of human spongiform encephalopathies; 
risk assessment of human spongiform encephalopathies; 
treatment  and  prevention  of  human  spongiform 
encephalopathies. 
(b)  Coordination between the  Member States of research  on  bovine 
spongiform  encephalopathy  (BSE)  and  subacute  spongiform 
encephalopathies. 
The resources necessary for the attainment of these objectives have been 
calculated on the basis of the following criteria: 
Each proposal will  on average comprise five  laboratories. 
The European Community's contribution to each laboratory should 
range between ECU I 0 000 and ECU I 00 000 per annum. 
These  objectives  will  be  attained  through  shared-cost  and  concerted 
actions.  These will  be enhanced by general  facilities  made available to 
researchers  and  through  targeted  training  for  them  (workshops, 
interdisciplinary conferences, studies, etc.). 
9.2  Tnr~et population 
Immediate  hcne.ficiaries:  Researchers  in  industry  and  111  the  academic 
world and also hospital clinicians and engineers. 
Ultimate  hencjiciaries:  The  citizens  of Europe  who  have  access  to 
research results, consumers, food  sectors, farmers. 
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J 9.3  Grounds for the operation 
The  spongiform  encephalopathies  (SE)  arc  a  group  of human  lethal 
neurodegenerativc transmissible diseases (Kuru, Creutzfeldt-Jakob disease 
(CJD), Gerstmann-Strausslcr-Scheinker disease (GSSD)) and animal lethal 
neurodegencrativc  transmissible  diseases  (scrapie,  bovine  spongiform 
encephalopathy (BSE)). 
An increasing amount of research is  being carried out on these diseases, 
on the one hand because of their particular biology and on the other hand 
because of concern about the possible transmission of the infective agents 
to  man.  It  is  therefore  essential  that  this  group  of diseases  be  given 
scientific priority.  This calls for an impetus being given to research efforts 
at Community level and the establishment of new scientific equilibria with 
a view to  attaining a critical  mass. 
9.4  Monitoring and evaluation of the operation 
The  operation  will  be  monitored  by  the  departments  of  the  DGs 
responsible  for  its  execution, ·with  the  support  of  the  Programme 
Committees. 
In order to contribute to the overall evaluation of  the Community activities 
provided  for  in  Article  4(2)  of the  Decision  establishing  the  fourth 
framework  programme  of  the  European  Community  for  research, 
technological  development and demonstration projects,  the  Commission 
will  in  due course instruct independent experts to  evaluate the  activities 
pursued  in  the  field  directly  covered  by  these  programmes  and  their 
management in the five years prior to such evaluation.  This operation will 
also be evaluated as part ofthc overall evaluation of  Community activities 
within the  fourth  framework  programme.  The Commission will  in  due 
course  instruct  independent  experts  to  carry  out  an  evaluation  of the 
activities  and  their  management  during  the  five  years  prior  to  such 
evaluation. 
An interim report and a final report will be drawn up on the contracts that 
will be signed within the framework of  the operation described in points 4 
and 9.1  above. 
In  drafting the fifth  framework programme, account will be taken of the 
following reports: 
Annual report of  the Commission on the research and technological 
development  activities  of the  European Union  based  on  Article 
130P of the EC Treaty. 
6 An  annual  report  on  the  continuous  monitoring of each  specific 
programme and of the framework programme.  This report will he 
compiled by independent experts. 
A five-yearly evaluation report of  each specific programme and of 
the framework programme.  This report will likewise be compiled 
by independent experts and will be published in  1996. 
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